{"id":"W4361026527","doi":"10.1016/s1470-2045(23)00063-3","title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital; Queen's University; Kingston Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Enzalutamide; Clinical endpoint; Prostate cancer; Internal medicine; Antiandrogen; Population; Flutamide; Oncology; Interim analysis; Bicalutamide; Testosterone (patch); Urology; Randomized controlled trial; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002023512,0.0004061558,0.001479947,0.0002281313,0.000414083,0.0001467386,0.000694857,0.0001719829,0.0001463939],"category_scores_gemma":[0.000411005,0.0002438685,0.0001176357,0.0004080503,0.0003550124,0.0004289868,0.0003731084,0.0004446875,0.00003370228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000940115,"about_ca_system_score_gemma":0.001399733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001995542,"about_ca_topic_score_gemma":0.0000959909,"domain_scores_codex":[0.9963876,0.000741692,0.0006071414,0.0007278841,0.0006259655,0.0009097332],"domain_scores_gemma":[0.9967611,0.001505644,0.0003550971,0.0006990023,0.0004045501,0.0002745443],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8755925,0.0008568862,0.0000378661,0.00005978081,0.0009386254,0.0002747695,0.00310236,0.00006834698,0.06420645,0.00002347086,0.02018414,0.03465481],"study_design_scores_gemma":[0.8860794,0.02597481,0.0001361103,0.0001636698,0.0004308747,0.00004026199,0.0009549119,0.003065481,0.0311203,0.0001732421,0.05157603,0.0002849268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9704241,0.001957974,0.00009091327,0.01194664,0.001999173,0.0112053,0.001689167,0.0001814899,0.0005052234],"genre_scores_gemma":[0.9594221,0.02057231,0.001917622,0.001534915,0.00224769,0.006973751,0.003231246,0.0001930495,0.003907386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03436988,"threshold_uncertainty_score":0.9944668,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.200267697456237,"score_gpt":0.4825725563967049,"score_spread":0.2823048589404679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}